Medscape
The Pharmacovigilance Risk Assessment Committee of the European Medicines Agency (EMA) has started a review of medicines containing finasteride and dutasteride following concerns about associated suicidal ideation and behaviors. Medicines containing finasteride (5 mg tablets) and dutasteride (0.5 mg capsules) are approved to treat symptoms of benign prostatic hyperplasia…
Read More
EMA Launches Review of Finasteride for Suicidal Ideation
Qiana Volkman
09:21
The Pharmacovigilance Risk Assessment Committee of the European Medicines Agency (EMA) has started a review of medicines containing finasteride and dutasteride following concerns about associated suicidal ideation and behaviors. Medicines containing finasteride (5 mg tablets) and dutasteride (0.5 mg capsules) are approved to treat symptoms of benign prostatic hyperplasia…
